Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23094114 | 0.97 | DGAT1 (0.50) | DGAT1FFAR3 | |
| SCHEMBL17586 | 0.89 | DGAT1 (0.43) | DGAT1FFAR3 | |
| SCHEMBL1786525 | 0.89 | DGAT1 (0.43) | DGAT1FFAR3 | |
| SCHEMBL25325201 | 0.88 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL696271 | 0.87 | DGAT1 (0.41) | DGAT1FFAR3 | |
| Hydrochloric Acid SCHEMBL12479454 | 0.85 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL21826042 | 0.83 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL5749625 | 0.83 | DGAT1 (0.39) | DGAT1 | |
| Hydrochloric Acid SCHEMBL1292454 | 0.81 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL27777472 | 0.79 | DGAT1 (0.54) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110872230-B | Preparation method of 1- (trifluoromethyl) cyclopropane-1-carboxylic acid compound and intermediate thereof | 浙江九洲药业股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-110054558-B | Preparation method of 1-trifluoromethylcyclopropane-1-formic acid | 海门瑞一医药科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-110872230-A | Preparation method and intermediate of 1- (trifluoromethyl) cyclopropane-1-carboxylic acid compound | 浙江九洲药业股份有限公司 | 2020-03-10 | — | — | CN | claimed |
| CN-110054558-A | A kind of preparation method of 1- trifluoromethyl cyclopropane -1- formic acid | 海门瑞一医药科技有限公司 | 2019-07-26 | — | — | CN | claimed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | claimed |
| CN-102958922-B | 2,5,6,7-tetrahydrochysene-[Isosorbide-5-Nitrae] oxygen azepine *-3-base amine or 2,3,6,7-tetrahydrochysene-[Isosorbide-5-Nitrae] oxygen azepine *-5-ylamine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2015-09-30 | — | — | CN | claimed |
| US-20140336208-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-13 | — | — | US | claimed |
| EP-2509966-B1 | AMINO OXAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | claimed |
| US-8815881-B2 | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-26 | — | — | US | claimed |
| EP-2566855-B1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-21 | — | — | EP | claimed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| JP-2007500717-A | — | — | 2007-01-18 | — | — | JP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | DGAT1 4434/4885FFAR3 668/4885 |
| US-20140336208-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | DGAT1 3613/4885FFAR3 3290/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | DGAT1 4625/4885FFAR3 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.